莱维体痴呆症:克服障碍并确定解决方案
Kanishka Agarwal1, Wendi Backler1, Ece Bayram2
1The Boston Consulting Group, Boston, Massachusetts, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|January 24, 2024
概括
莱维体痴呆症 (LBD) 研究和护理面临着重大差距,特别是在治疗开发方面. 专家们召开会议以确定加速治疗和改善这种研究不足的痴呆症患者治疗结果的优先事项.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 公共卫生 公共卫生
背景情况:
- 莱维体痴呆症 (LBD) 是一种流行但不太了解的痴呆症.
- 重叠的病理和缺乏治疗方法加剧了LBD的公共卫生负担.
- 误诊是常见的,因为病理重叠.
研究的目的:
- 确定倡导,资金,研究成果和LBD治疗管道中的关键缺口.
- 通过专家采访和数据分析来了解当前的挑战.
- 提出一个合作框架,以弥合所发现的差距.
主要方法:
- 对公共领域关于LBD宣传,资助,研究和治疗方法的信息的分析.
- 采访来自监管,宣传,学术和生物制药领域的专家.
- 一个涉及专家的研讨会,优先考虑LBD的研究领域.
主要成果:
- 在所有分析的LBD景观元素中发现了显著的差距.
- 研究差距是最关键的,阻碍治疗开发.
- 专家共识确定了加速LBD研究和护理的重点优先事项.
结论:
- 弥合发现的差距需要一个协作框架.
- 优先考虑研究对于推动LBD治疗开发至关重要.
- 白皮书概述了改善LBD患者护理和结果的机会.
相关概念视频
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
Ethical Dilemmas II
1.1K
Resolving an ethical dilemma in healthcare involves a systematic approach that considers every aspect of the issue, respecting both the patient's needs and values and the healthcare professional's ethical obligations. Here are potential steps to resolve an ethical dilemma:
1.1K


